Back to Journals » Lung Cancer: Targets and Therapy » Volume 11

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin

Authors Kauffmann-Guerrero D, Huber RM

Received 19 November 2019

Accepted for publication 7 February 2020

Published 2 March 2020 Volume 2020:11 Pages 27—31

DOI https://doi.org/10.2147/LCTT.S239223

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Sai-Hong Ignatius Ou


Diego Kauffmann-Guerrero, Rudolf Maria Huber

Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, Germany

Correspondence: Diego Kauffmann-Guerrero
Hospital of the University of Munich (LMU), Ziemssenstraße 1, Munich 80336, Germany
Tel +49-89-4400-52187
Email KauffmannGuerrero@med.uni-muenchen.de

Abstract: Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatment remains poor. For years, no relevant improvement of second line treatment has been achieved in the field of SCLC. Lurbinectedin, a novel RNA-polymerase II inhibitor has shown promising results in pretreated SCLC patients as single agent and in combination with other chemotherapeutic drugs leading to an orphan drug designation from the FDA. This article reviews the current data on this emerging substance and its impact on the treatment of SCLC.

Keywords: SCLC, chemotherapy, lurbinectedin, orphan drug

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]